Stifel is moving off the sidelines when it comes to Biogen . The investment firm upgraded the biotech stock to buy from hold. It also hiked its target price to $202 per share from $144, which signals upside of nearly 32% from Wednesday's close. Analyst Paul Matteis' forecast implies that the stock could rally nearly 32% from here. BIIB YTD mountain BIIB YTD chart "For a cheaper, 'value-y' large cap, Biogen offers unique optionality even if clinical catalysts still have risks," he wrote. "Valuation isn't a thesis in its own right in biotech, but on a EV/sales basis Biogen trades well below peers." Matteis clarified that his upgrade was not a call on the base business, pointing to the company's "mixed" third-quarter results and a fourth-quarter report that should be "just okay." Instead, he

See Full Page